$CTNM News
Last published 2d ago
- 2d agoCTNMQureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical TrialBusiness WireCAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum) (NASDAQ:CTNM), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with signif ...
- 1w agoCTNMContineum Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoCTNMContineum Therapeutics to Present at the Stifel 2026 Healthcare ConferenceBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with
- 1mo agoCTNMContineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive DisorderBusiness WirePhase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint Analyses of the data, including prespecified exploratory endpoints, are ongoing Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the
- 2mo agoCTNMContineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare ConferenceBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with
- 3mo agoCTNMContineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development MilestonesBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with
- 4mo agoCTNMContineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal ChemistryBusiness Wire- Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF)- Blocking LPAR1 inhibits key steps in the fibrosis pathway with
- 5mo agoCTNMContineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare ConferenceBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 6mo agoCTNMContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 6mo agoCTNMContineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare ConferenceBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 6mo agoCTNMContineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International ConferenceBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 6mo agoCTNMContineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development MilestonesBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 6mo agoCTNMContineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 6mo agoCTNMContineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic PainBusiness Wire- The trial achieved its primary endpoint demonstrating favorable safety and tolerability - Encouraging trends observed across multiple exploratory efficacy endpoints including improvements in measures of pain and
- 8mo agoCTNMContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 8mo agoCTNMContineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development MilestonesBusiness Wire- Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF) - Topline data from the exploratory PIPE-791 Phase 1b trial
- 8mo agoCTNMContineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare ConferenceBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 8mo agoCTNMContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 9mo agoCTNMContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 11mo agoCTNMContineum Therapeutics Announces Pricing of Upsized $90.0 Million Public OfferingBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 11mo agoCTNMContineum Therapeutics Announces Proposed $75.0 Million Public OfferingBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 11mo agoCTNMContineum Therapeutics to Attend the 8th Annual Evercore Healthcare ConferenceBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 11mo agoCTNMContineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)Business Wire- PIPE-307 demonstrated an acceptable safety and tolerability profile - PIPE-307 treatment did not result in a significant change in binocular 2.5% low contrast letter acuity (LCLA) Contineum Therapeutics, Inc.
- 1y agoCTNMContineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development MilestonesBusiness Wire- Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025 - Initiation of a global Phase 2 clinical trial of
- 1y agoCTNMContineum Therapeutics to Present at September Investor ConferencesBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 1y agoCTNMContineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development MilestonesBusiness Wire- Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025 - Initiation of a global Phase 2 proof-of-concept
- 1y agoCTNMContineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791Business WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 1y agoARTVCTNMArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board ChairBusiness WireArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery,
- 1y agoCTNMContineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare ConferenceBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 1y agoCTNMContineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development MilestonesBusiness Wire- Topline data from PIPE-791 Phase 1b positron emission tomography (PET) trial expected in the second quarter of 2025 - PIPE-791 chronic toxicity studies completed to support future Phase 2 trials - Topline data from
- 1y agoCTNMGILDContineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of DevelopmentBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 1y agoCTNMContineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of DirectorsBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 1y agoCTNMContineum Therapeutics to Present at the Stifel 2025 Virtual CNS ForumBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 1y agoCTNMContineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development MilestonesBusiness Wire- Topline data from PIPE-791 Phase 1b positron emission tomography (PET) trial expected in the second quarter of 2025 - Topline data from PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple
- 1y agoCTNMContineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791Business Wire- Exploratory phase 1b trial will evaluate safety, tolerability and effect on pain intensity - Topline data readout planned for early 2026 Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a
- 1y agoCTNMContineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare ConferenceBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology
- 1y agoCTNMContineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)Business Wire- Targeted enrollment of 168 RRMS patients achieved in December 2024 - The last patient is expected to complete the trial in the third quarter of 2025 Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the
- 1y agoCTNMRAPTRAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing
- 1y agoCTNMContineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791Business Wire- Phase 1b trial will evaluate receptor occupancy of PIPE-791 in the brain and lungs of patients in multiple cohorts using a PET tracer of the LPA1 receptor - Topline data readout planned for the second quarter of
- 1y agoCTNMContineum Therapeutics to Attend the 7th Annual Evercore HealthCONx ConferenceBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological
- 1y agoCTNMContineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic PainBusiness Wire- Phase 1b study for the potential treatment of osteoarthritis and low back pain expected to commence in the first quarter of 2025 - Initial data readout planned for early 2026 - Neuropathic component of chronic pain
- 1y agoCTNMContineum Therapeutics to Attend Upcoming Investor ConferencesBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological
- 2y agoCTNMContineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire-Enrollment for PIPE-307 VISTA trial on track- -Strong cash position of $214 million at the end of Q3 expected to support operations through 2027- -Multiple potential clinical readouts in 2025- Contineum
- 2y agoCTNMContineum Therapeutics to Present at Multiple Upcoming Investor ConferencesBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific
- 2y agoCTNMRAPPRNAContineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire- Strengthened Board and management with appointments of experienced biotech leaders Troy Ignelzi, Sarah Boyce, John Healy and Kristina Haeckl - - Strong cash position of $219 million at the end of Q2 will support
- 2y agoCTNMContineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple SclerosisBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific
- 2y agoCTNMIONSNVSRNA+2Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of DirectorsBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific
- 2y agoCTNMContineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare ConferenceBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific
- 2y agoCTNMContineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate SecretaryBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific
- 2y agoCTNMContineum Therapeutics Announces Appointment of Troy Ignelzi to Board of DirectorsBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific